Login Register Cart 0
Generic placeholder image

Current Drug Delivery

Editor-in-Chief

ISSN (Print): 1567-2018
ISSN (Online): 1875-5704

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Perspective

Inhaled Lipid Nanoparticles: A Feasible Tool for a Challenging Route

Author(s): Eliana Leo* and Eleonora Maretti

Volume 21, Issue 3, 2024

Published on: 21 February, 2023

Page: [309 - 311] Pages: 3

DOI: 10.2174/1567201820666230210161253

Price: $65

Next »
[1]
Truzzi, E.; Rustichelli, C.; de Oliveira, E.R., Junior; Ferraro, L.; Maretti, E.; Graziani, D.; Botti, G.; Beggiato, S.; Iannuccelli, V.; Lima, E.M.; Dalpiaz, A.; Leo, E. Nasal biocompatible powder of Geraniol oil complexed with cyclodextrins for neurodegenerative diseases: physicochemical characterization and in vivo evidences of nose to brain delivery. J. Control. Release, 2021, 335, 191-202.
[http://dx.doi.org/10.1016/j.jconrel.2021.05.020] [PMID: 34019946]
[2]
de Oliveira, E.R., Junior; Truzzi, E.; Ferraro, L.; Fogagnolo, M.; Pavan, B.; Beggiato, S.; Rustichelli, C.; Maretti, E.; Lima, E.M.; Leo, E.; Dalpiaz, A. Nasal administration of nanoencapsulated geraniol/ursodeoxycholic acid conjugate: Towards a new approach for the management of Parkinson’s disease. J. Control. Release, 2020, 321, 540-552.
[http://dx.doi.org/10.1016/j.jconrel.2020.02.033] [PMID: 32092370]
[3]
Kubczak, M.; Michlewska, S.; Bryszewska, M.; Aigner, A.; Ionov, M. Nanoparticles for local delivery of siRNA in lung therapy. Adv. Drug Deliv. Rev., 2021, 179, 114038.
[http://dx.doi.org/10.1016/j.addr.2021.114038] [PMID: 34742826]
[4]
Mehnert, W.; Mäder, K. Solid lipid nanoparticles. Adv. Drug Deliv. Rev., 2012, 64, 83-101.
[http://dx.doi.org/10.1016/j.addr.2012.09.021] [PMID: 11311991]
[5]
Truzzi, E.; Nascimento, T.L.; Iannuccelli, V.; Costantino, L.; Lima, E.M.; Leo, E.; Siligardi, C.; Gualtieri, M.L.; Maretti, E. In vivo biodistribution of respirable solid lipid nanoparticles surface-decorated with a mannose-based surfactant: a promising tool for pulmonary tuberculosis treatment? Nanomaterials (Basel), 2020, 10(3), 568.
[http://dx.doi.org/10.3390/nano10030568] [PMID: 32245153]
[6]
Truzzi, E.; Meneghetti, F.; Mori, M.; Costantino, L.; Iannuccelli, V.; Maretti, E.; Domenici, F.; Castellano, C.; Rogers, S.; Capocefalo, A.; Leo, E. Drugs/lamellae interface influences the inner structure of double-loaded liposomes for inhaled anti-TB therapy: An in-depth small-angle neutron scattering investigation. J. Colloid Interface Sci., 2019, 541, 399-406.
[http://dx.doi.org/10.1016/j.jcis.2019.01.094] [PMID: 30710822]
[7]
Rabiei, M.; Kashanian, S.; Samavati, S.S.; Derakhshankhah, H.; Jamasb, S.; McInnes, S.J.P. Characteristics of SARS-CoV2 that may be useful for nanoparticle pulmonary drug delivery. J. Drug Target., 2022, 30(3), 233-243.
[http://dx.doi.org/10.1080/1061186X.2021.1971236] [PMID: 34415800]
[8]
Mitchell, M.J.; Billingsley, M.M.; Haley, R.M.; Wechsler, M.E.; Peppas, N.A.; Langer, R. Engineering precision nanoparticles for drug delivery. Nat. Rev. Drug Discov., 2021, 20(2), 101-124.
[http://dx.doi.org/10.1038/s41573-020-0090-8] [PMID: 33277608]
[9]
Sou, T.; Bergström, C.A.S. Contemporary formulation development for inhaled pharmaceuticals. J. Pharm. Sci., 2021, 110(1), 66-86.
[http://dx.doi.org/10.1016/j.xphs.2020.09.006] [PMID: 32916138]
[10]
Chen, D.; Liu, J.; Wu, J.; Suk, J.S. Enhancing nanoparticle penetration through airway mucus to improve drug delivery efficacy in the lung. Expert Opin. Drug Deliv., 2021, 18(5), 595-606.
[http://dx.doi.org/10.1080/17425247.2021.1854222] [PMID: 33218265]
[11]
He, S.; Gui, J.; Xiong, K.; Chen, M.; Gao, H.; Fu, Y. A roadmap to pulmonary delivery strategies for the treatment of infectious lung diseases. J. Nanobiotechnology, 2022, 20(1), 101.
[http://dx.doi.org/10.1186/s12951-022-01307-x] [PMID: 35241085]
[12]
Garcia-Mouton, C.; Hidalgo, A.; Cruz, A.; Pérez-Gil, J. The Lord of the Lungs: The essential role of pulmonary surfactant upon inhalation of nanoparticles. Eur. J. Pharm. Biopharm., 2019, 144, 230-243.
[http://dx.doi.org/10.1016/j.ejpb.2019.09.020] [PMID: 31560956]
[13]
Herman, L.; De Smedt, S.C.; Raemdonck, K. Pulmonary surfactant as a versatile biomaterial to fight COVID-19. J. Control. Release, 2022, 342, 170-188.
[http://dx.doi.org/10.1016/j.jconrel.2021.11.023] [PMID: 34813878]
[14]
Maretti, E.; Rustichelli, C.; Lassinantti Gualtieri, M.; Costantino, L.; Siligardi, C.; Miselli, P.; Buttini, F.; Montecchi, M.; Leo, E.; Truzzi, E.; Iannuccelli, V. The impact of lipid corona on rifampicin intramacrophagic transport using inhaled solid lipid nanoparticles surface-decorated with a mannosylated surfactant. Pharmaceutics, 2019, 11(10), 508.
[http://dx.doi.org/10.3390/pharmaceutics11100508] [PMID: 31581554]
[15]
Liu, Q.; Guan, J.; Song, R.; Zhang, X.; Mao, S. Physicochemical properties of nanoparticles affecting their fate and the physiological function of pulmonary surfactants. Acta Biomater., 2022, 140, 76-87.
[http://dx.doi.org/10.1016/j.actbio.2021.11.034] [PMID: 34843949]
[16]
Sawarkar, S.; Prabhu, P.; Fernandes, T.; Damani, M.; Chaubey, P.; Narayanan, S. 2 Receptor specific ligand conjugated nanocarriers: an effective strategy for targeted therapy of tuberculosis. Curr. Drug Deliv., 2022, 19(8), 830-845.
[http://dx.doi.org/10.2174/1567201819666211216141942] [PMID: 34915835]
[17]
Bain, C.C.; Rossi, A.G.; Lucas, C.D. Pulmonary macrophages and SARS-Cov2 infection. Int. Rev. Cell Mol. Biol., 2022, 367, 1-28.
[http://dx.doi.org/10.1016/bs.ircmb.2022.01.001] [PMID: 35461655]
[18]
Schwab, C.; Domke, L.M.; Rose, F.; Hausser, I.; Schirmacher, P.; Longerich, T. Cell tropism and viral clearance during SARS-CoV-2 lung infection. Pathol. Res. Pract., 2022, 236, 154000.
[http://dx.doi.org/10.1016/j.prp.2022.154000] [PMID: 35797854]
[19]
Hussain, A.; Singh, S.; Das, S.S.; Anjireddy, K.; Karpagam, S.; Shakeel, F. Nanomedicines as drug delivery carriers of anti-tubercular drugs: from pathogenesis to infection control. Curr. Drug Deliv., 2019, 16(5), 400-429.
[http://dx.doi.org/10.2174/1567201816666190201144815] [PMID: 30714523]
[20]
Lynch, H.F.; Robertson, C.T. Challenges in confirming drug effectiveness after early approval. Science, 2021, 374(6572), 1205-1207.
[http://dx.doi.org/10.1126/science.abk3495] [PMID: 34855490]
[21]
Maretti, E.; Costantino, L.; Buttini, F.; Rustichelli, C.; Leo, E.; Truzzi, E.; Iannuccelli, V. Newly synthesized surfactants for surface mannosylation of respirable SLN assemblies to target macrophages in tuberculosis therapy. Drug Deliv. Transl. Res., 2019, 9(1), 298-310.
[http://dx.doi.org/10.1007/s13346-018-00607-w] [PMID: 30484257]
[22]
Dalpiaz, A.; Fogagnolo, M.; Ferraro, L.; Beggiato, S.; Hanuskova, M.; Maretti, E.; Sacchetti, F.; Leo, E.; Pavan, B. Bile salt-coating modulates the macrophage uptake of nanocores constituted by a zidovudine prodrug and enhances its nose-to-brain delivery. Eur. J. Pharm. Biopharm., 2019, 144, 91-100.
[http://dx.doi.org/10.1016/j.ejpb.2019.09.008] [PMID: 31521715]

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy